# Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer

> **NCT02188264** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Recurrent Colorectal Carcinoma
- Solid Neoplasm
- Stage IIIA Colorectal Cancer AJCC v7
- Stage IIIB Colorectal Cancer AJCC v7
- Stage IIIC Colorectal Cancer AJCC v7
- Stage IVA Colorectal Cancer AJCC v7
- Stage IVB Colorectal Cancer AJCC v7

## Interventions

- **DRUG:** Cyclosporine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT02188264
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-29
- **Primary completion:** 2017-01-31
- **Final completion:** 2019-04-26
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02188264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02188264, "Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02188264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*